4 completed, 4 recruiting, 2 terminated. 9 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Recruiting 3, Terminated 2 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow ORIC Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) Rinzimetostat, Darolutamide, Enzalutamide - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Recruiting | ORIC Pharmaceuticals | 600 | 2026-08-03 | 2026-10-05 |
| ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC ORIC-114 Dose 1 + amivantamab, ORIC-114 Dose 2 + amivantamab, ORIC-114 Dose 3 + amivantamab - Solid Tumors, EGFR Exon 20 Insertion Mutations | Phase 1 | Recruiting | ORIC Pharmaceuticals | 76 | 2025-02-27 | 2026-04-24 |
| Effect of Food on the Pharmacokinetics of ORIC-114 ORIC-114 - Food Effect in Healthy Participants | Phase 1 | Completed | ORIC Pharmaceuticals | 32 | 2023-09-11 | 2024-01-19 |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets - Metastatic Prostate Cancer | Phase 1 | Recruiting | ORIC Pharmaceuticals | 275 | 2022-06-01 | 2026-07-09 |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration ORIC-114, Chemotherapy drug - Solid Tumors | Phase 1 / Phase 2 | Recruiting | ORIC Pharmaceuticals | 350 | 2022-03-10 | 2026-09-04 |
| Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma ORIC-533 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Completed | ORIC Pharmaceuticals | 31 | 2022-01-06 | 2025-03-20 |
| Study of ORIC-101 in Combination With Enzalutamide ORIC-101, enzalutamide 40 MG oral capsule [Xtandi] - Prostatic Neoplasms | Phase 1 | Terminated | ORIC Pharmaceuticals | 41 | 2019-10-28 | 2023-12-15 |
| Study of ORIC-101 in Combination With Anticancer Therapy ORIC-101, Nab-paclitaxel - Solid Tumor | Phase 1 | Terminated | ORIC Pharmaceuticals | 83 | 2019-05-02 | 2023-12-15 |
| Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects ORIC-101 - Healthy Volunteers | Phase 1 | Completed | ORIC Pharmaceuticals | 32 | 2018-03-23 | 2019-02-08 |
| Study of ORIC-101 in Healthy Adult Subjects ORIC-101 - Healthy Volunteers | Phase 1 | Completed | ORIC Pharmaceuticals | 24 | 2017-10-19 | 2018-04-05 |
Prostatic Neoplasms (3) · Recurrence (2) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Multiple Myeloma (1)
enzalutamide (3) · darolutamide (2) · 130-nm albumin-bound paclitaxel (1) · Abiraterone Acetate (1) · Carboplatin (1) · Docetaxel (1) · Pemetrexed (1) · amivantamab (1) · apalutamide (1)
United States (8) · Australia (4) · Canada (3) · United Kingdom (3) · Spain (2) · Hong Kong (1) · Malaysia (1) · Poland (1) · Puerto Rico (1) · South Korea (1) · Taiwan (1)
Pratik S. Multani, MD (4) · Pratik S. Multani, MD, MS (2) · Pratik S Multani, MD, MS (1)